Oncology Corporate Profile
Immunovaccine Inc. develops cancer immunotherapies and infectious disease vaccines based on the Company’s DepoVax™ platform, a patented formulation that provides controlled and prolonged exposure of antigens and adjuvants to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase I human clinical trials. Lead cancer vaccine therapy, DPX-Survivac, is expected to enter Phase II clinical studies in 2014, in ovarian cancer and glioblastoma (brain cancer). The Company is also advancing an infectious disease pipeline including innovative vaccines for respiratory syncytial virus (RSV) and anthrax.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|DPX-0907||immunotherapy||Diffuse large B-cell Lymphoma (DLBCL)||II|
|DPX-Survivac (+ INCB24360||immunotherapy||Various cancer types||I||Incyte|
|DPX-Survivac||immunotherapy||Various cancer types||I|
View additional information on product candidates here »